BridgeBio Pharma Prices $550 Million Convertible Notes at 0.75% Interest Rate
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Financing Size: BridgeBio Pharma announced the pricing of $550 million in 0.75% convertible notes, expected to close on January 21, 2026, aimed at reducing interest expenses and extending debt maturity.
- Use of Proceeds: The company plans to utilize approximately $538.4 million in net proceeds to repurchase a portion of its 2.50% convertible notes due 2027, enhancing financial flexibility and reducing future dilution risks.
- Share Repurchase Plan: BridgeBio will use about $82.5 million in cash to repurchase approximately 1.1 million shares of common stock, which is expected to boost market prices and may influence the initial conversion price of the notes.
- Conversion Terms: The initial conversion price of the notes is approximately $110.58 per share, representing a 45% premium over the last reported price on January 15, 2026, providing holders with potential capital appreciation opportunities.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 84.20 USD with a low forecast of 64.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 77.900
Low
64.00
Averages
84.20
High
100.00
Current: 77.900
Low
64.00
Averages
84.20
High
100.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
